Search

everythinglearnresearchcommunity

for

Search:↓

Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Baricitinib may not always prevent relapse in alopecia areata.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Individual choice in treating alopecia areata greatly impacts quality of life.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

The treatment showed promising hair regrowth in advanced-stage hair loss.

ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

Alefacept does not effectively treat severe alopecia areata.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

The document's conclusion cannot be provided because the content is not available.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Platelet rich plasma was slightly more effective than no treatment for hair loss in alopecia areata patients.

Botulinum toxin type A did not help regrow hair in severe alopecia cases.

Antioxidants can block the cancer-fighting effects of doxorubicin.